Novo Nordisk A/S stated it’s going to take an impairment of about 5.7 billion Danish kroner ($820 million) after halting a late-stage research of an experimental coronary heart drug it acquired final 12 months.
The Danish drugmaker stopped the trial partway by, after an unbiased monitoring committee concluded that it hadn’t hit its primary purpose of adjusting blood strain after 12 weeks. The research of greater than 600 sufferers, Clarion-CKD, had regarded on the compound ocedurenone in sufferers with uncontrolled hypertension and superior persistent kidney illness.
Novo agreed final 12 months to pay KBP BioSciences as a lot as $1.3 billion for ocedurenone, a part of the Ozempic maker’s effort to broaden from its core diabetes remedy portfolio into different critical illnesses.
The failure is a uncommon setback for Novo, which is driving excessive on the success of its weight problems medication.
The drugmaker had envisioned ocedurenone addressing a serious want for individuals with each coronary heart illness and persistent kidney illness, its executives stated when the deal was introduced in October. The corporate had deliberate to check the compound throughout several types of coronary heart and kidney illness. Novo is now re-evaluating that plan, it stated Wednesday.
The failed compound is a part of a brand new class of capsules known as non-steroidal mineralocorticoid receptor antagonists, or nsMRAs, that features Bayer AG’s predicted blockbuster Kerendia.
Novo shares traded as a lot as 2.4% decrease in Copenhagen. The inventory has soared greater than 40% this 12 months.
